References

Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R

10.1002/(sici)1097-0215(19980413)76:2<223::aid-ijc9>3.0.co;2-z · 1998 · External reference

The insulin-like growth factor system and sarcomas

10.1002/path.2499 · 2009 · External reference

Expression of insulin-like growth factor 1 in sarcomas

10.1111/j.1365-2559.1990.tb01544.x · 1990 · External reference

Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors

10.1158/0008-5472.can-11-3015 · 2012 · External reference

Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571

2002 · External reference

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

10.1016/s0002-9440(10)64946-2 · 2000 · External reference

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

2001 · External reference

The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit

1995 · External reference

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas

1996 · External reference

Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma

10.1016/s0046-8177(00)80218-x · 2000 · External reference

Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations

10.1007/s00428-009-0776-0 · 2010 · External reference

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

10.1126/science.279.5350.577 · 1998 · External reference

C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions

10.1200/jco.2003.11.111 · 2003 · External reference

C-kit expression in pediatric solid tumors: a comparative immunohistochemical study

10.1097/00000478-200204000-00011 · 2002 · External reference

PDGFRA activating mutations in gastrointestinal stromal tumors

10.1126/science.1079666 · 2003 · External reference

Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT

10.1200/jco.2007.13.4403 · 2008 · External reference

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

10.1200/jco.2007.13.4452 · 2008 · External reference

The role of focal-adhesion kinase in cancer—a new therapeutic opportunity

10.1038/nrc1647 · 2005 · External reference

Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways

10.1016/s0955-0674(97)80062-2 · 1997 · External reference

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

10.1074/jbc.274.12.8335 · 1999 · External reference

c-Src and cooperating partners in human cancer

10.1016/j.ccr.2004.09.001 · 2004 · External reference

Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model

10.1593/neo.03334 · 2004 · External reference

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

10.1038/labinvest.3700080 · 2004 · External reference

Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas

10.1002/jso.20973 · 2008 · External reference

Spontaneously occurring tumors of companion animals as models for human cancer

10.3109/07357900009012210 · 2000 · External reference

Biological and molecular characterization of a canine hemangiosarcoma-derived cell line

10.1016/j.rvsc.2005.09.005 · 2006 · External reference

Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed

10.1371/journal.pone.0005549 · 2009 · External reference

Activating alleles of JAK3 in acute megakaryoblastic leukemia

10.1016/j.ccr.2006.06.002 · 2006 · External reference

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

10.1073/pnas.0800587105 · 2008 · External reference

Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes

10.1186/1471-2407-9-363 · 2009 · External reference

Mechanism of action and in vivo role of platelet-derived growth factor

10.1152/physrev.1999.79.4.1283 · 1999 · External reference

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

10.1182/blood-2007-07-102061 · 2007 · External reference

A case study of personalized therapy for osteosarcoma

10.1002/pbc.24512 · 2013 · External reference

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

10.1200/jco.2009.24.2099 · 2010 · External reference

Soft-tissue sarcomas in adults

10.1056/nejmra041866 · 2005 · External reference

Soft tissue sarcoma

10.6004/jnccn.2010.0049 · 2010 · External reference

Cancer statistics, 2010

2010 · External reference

Spontaneous and genetically engineered animal models; use in preclinical cancer drug development

10.1016/j.ejca.2003.11.031 · 2004 · External reference

Translation of new cancer treatments from pet dogs to humans

10.1038/nrc2273 · 2008 · External reference

Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach

10.1016/j.bone.2011.05.008 · 2011 · External reference

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma

10.1186/1471-2407-10-619 · 2010 · External reference

Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

10.1242/dev.126.14.3047 · 1999 · External reference

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

10.1016/s0022-3565(24)38879-2 · 2000 · External reference

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

10.1172/jci200318549 · 2003 · External reference

Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate

10.1158/0008-5472.can-03-1489 · 2004 · External reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

10.1172/jci200317929 · 2003 · External reference

Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma

10.1111/j.1476-5829.2012.00325.x · 2012 · External reference

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs

10.1111/j.1939-1676.2008.00132.x · 2008 · External reference

Tyrosine kinase inhibitors in veterinary medicine

10.1053/j.tcam.2009.02.002 · 2009 · External reference

Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs

10.1080/00498250600962849 · 2007 · External reference

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells

10.1016/j.exphem.2007.06.005 · 2007 · External reference

Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

10.1021/jm049486a · 2004 · External reference

EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy

10.1038/sj.onc.1210684 · 2008 · External reference

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

10.1158/1078-0432.ccr-07-5226 · 2008 · External reference

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines

10.2353/ajpath.2007.060706 · 2007 · External reference

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab

10.4161/cbt.8.8.7903 · 2009 · External reference